{
  "docId": "019de075-ba14-74ac-bf24-b9a07d855845",
  "docSlug": "ce85efab4cdfea0a9273e6eac7085298",
  "documentTitle": "MindMed | Investor Presentation Deck | 32 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 32,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a bulleted list to highlight key company strengths and specific clinical trial statuses for MM-120 and MM-402.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ba14-74ac-bf24-b9a07d855845/31",
  "deckHref": "/decks/019de075-ba14-74ac-bf24-b9a07d855845",
  "deckJsonHref": "/decks/019de075-ba14-74ac-bf24-b9a07d855845.json",
  "deckAnchorHref": "/decks/019de075-ba14-74ac-bf24-b9a07d855845#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.058,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "1. The company's ending Q2 2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e56a0434-8195-455e-b2d3-847dfefce9a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.88,
        "x": 0.058,
        "y": 0.16
      },
      "kind": "list",
      "text": "A leader in developing psychedelic product candidates to treat brain health disorders; Diversified pipeline of clinical programs; IP and R&D strategies; Leveraging decades of research; Expertise in drug and digital medicine; Expected cash runway into 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "378d6115-eb41-478e-99d6-e5c0bfc70900",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.058,
        "y": 0.53
      },
      "kind": "list",
      "text": "MM-120 (LSD D-tartrate) for the treatment of GAD and ADHD: Phase 2b dose-optimization study ongoing (Q4 2023); Phase 2a study ongoing (Q4 2023 / Q1 2024)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95a2459f-d0fa-44e7-b7c4-506256affb02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.058,
        "y": 0.7
      },
      "kind": "list",
      "text": "MM-402 or R(-)-MDMA for the treatment of core symptoms of ASD: IND-enabling studies ongoing (Q4 2023); Phase 1 investigator-initiated trial ongoing (H1 2024)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9ca6320-6f61-42f3-9d42-51609c0be567",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.058,
        "y": 0.048
      },
      "kind": "title",
      "text": "Business Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "440e8a3a-e259-4a37-a830-5b835f1ff35c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}